ProPhase Labs (PRPH)
(Delayed Data from NSDQ)
$0.33 USD
-0.03 (-9.34%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $0.33 0.00 (1.20%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PRPH 0.33 -0.03(-9.34%)
Will PRPH be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PRPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PRPH
Vivos Therapeutics, Inc. (VVOS) Reports Q1 Loss, Lags Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Lags Revenue Estimates
PRPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Inotiv, Inc. (NOTV) Reports Q2 Loss, Tops Revenue Estimates
BioCryst Pharmaceuticals (BCRX) Reports Break-Even Earnings for Q1
Durect (DRRX) Reports Q4 Loss, Lags Revenue Estimates
Other News for PRPH
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
ProPhase Labs (PRPH) Seeks Shareholder Approval to Expand Share Authorization
ProPhase Labs announces special meeting of shareholders
ProPhase Labs Announces Special Meeting of Shareholders and Filing of Preliminary Proxy ...